Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis.

Rosenbach M, Yeung H, Chu EY, Kim EJ, Payne AS, Takeshita J, Vittorio CC, Wanat KA, Werth VP, Gelfand JM.

JAMA Dermatol. 2013 May;149(5):550-6. doi: 10.1001/jamadermatol.2013.60.

2.

Reliability and Validity of Cutaneous Sarcoidosis Outcome Instruments Among Dermatologists, Pulmonologists, and Rheumatologists.

Yeung H, Farber S, Birnbaum BK, Dunham J, Ogdie A, Patterson KC, Payne AS, Porteous MK, Rossman MD, Sharim R, Takeshita J, Werth VP, Shin DB, Price S, Rosenbach M.

JAMA Dermatol. 2015 Dec 1;151(12):1317-1322. doi: 10.1001/jamadermatol.2015.2008.

PMID:
26266830
3.

Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).

Loh CC, Kim J, Su JC, Daniel BS, Venugopal SS, Rhodes LM, Intong LR, Law MG, Murrell DF.

J Am Acad Dermatol. 2014 Jan;70(1):89-97.e1-13. doi: 10.1016/j.jaad.2013.09.041.

PMID:
24355263
4.

Reliability and convergent validity of two outcome instruments for pemphigus.

Rosenbach M, Murrell DF, Bystryn JC, Dulay S, Dick S, Fakharzadeh S, Hall R, Korman NJ, Lin J, Okawa J, Pandya AG, Payne AS, Rose M, Rubenstein D, Woodley D, Vittorio C, Werth BB, Williams EA, Taylor L, Troxel AB, Werth VP.

J Invest Dermatol. 2009 Oct;129(10):2404-10. doi: 10.1038/jid.2009.72. Epub 2009 Apr 9.

5.
6.
7.

Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis.

Klein RQ, Bangert CA, Costner M, Connolly MK, Tanikawa A, Okawa J, Rose M, Fakharzadeh SS, Fiorentino D, Lee LA, Sontheimer RD, Taylor L, Troxel AB, Werth VP.

Br J Dermatol. 2008 Sep;159(4):887-94. doi: 10.1111/j.1365-2133.2008.08711.x. Epub 2008 Jul 4.

8.

The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures.

Arkachaisri T, Vilaiyuk S, Li S, O'Neil KM, Pope E, Higgins GC, Punaro M, Rabinovich EC, Rosenkranz M, Kietz DA, Rosen P, Spalding SJ, Hennon TR, Torok KS, Cassidy E, Medsger TA Jr; Localized Scleroderma Clinical and Ultrasound Study Group.

J Rheumatol. 2009 Dec;36(12):2819-29. doi: 10.3899/jrheum.081284. Epub 2009 Oct 15.

10.

Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM.

Goreshi R, Okawa J, Rose M, Feng R, Lee LA, Hansen CB, Bangert CA, Connolly MK, Davis MD, Callen JP, Fett NM, Fakharzadeh SS, Clarke JT, Werth VP.

J Invest Dermatol. 2012 Apr;132(4):1117-24. doi: 10.1038/jid.2011.440. Epub 2012 Jan 5.

11.

Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire.

Sebaratnam DF, Hanna AM, Chee SN, Frew JW, Venugopal SS, Daniel BS, Martin LK, Rhodes LM, Tan JC, Wang CQ, Welsh B, Nijsten T, Murrell DF.

JAMA Dermatol. 2013 Oct;149(10):1186-91. doi: 10.1001/jamadermatol.2013.4972.

PMID:
23925444
12.

Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems.

Baughman RP, Judson MA, Teirstein A, Lower EE, Lo K, Schlenker-Herceg R, Barnathan ES.

Am J Clin Dermatol. 2008;9(3):155-61.

PMID:
18429644
13.

Validation of the dyspnea index in adolescents with exercise-induced paradoxical vocal fold motion.

De Guzman V, Ballif CL, Maurer R, Hartnick CJ, Raol N.

JAMA Otolaryngol Head Neck Surg. 2014 Sep;140(9):823-8. doi: 10.1001/jamaoto.2014.1405.

PMID:
25104182
14.

Measurement properties of the Vitiligo Impact Scale-22 (VIS-22), a vitiligo-specific quality-of-life instrument.

Gupta V, Sreenivas V, Mehta M, Khaitan BK, Ramam M.

Br J Dermatol. 2014 Nov;171(5):1084-90. doi: 10.1111/bjd.13093. Epub 2014 Oct 6.

PMID:
24805089
15.

A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index.

Berth-Jones J, Thompson J, Papp K; Copenhagen Psoriasis Working Group.

Br J Dermatol. 2008 Aug;159(2):407-12. doi: 10.1111/j.1365-2133.2008.08680.x. Epub 2008 Jun 28.

PMID:
18565187
16.

Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score.

Rahbar Z, Daneshpazhooh M, Mirshams-Shahshahani M, Esmaili N, Heidari K, Aghazadeh N, Hejazi P, Ghajarzadeh M, Chams-Davatchi C.

JAMA Dermatol. 2014 Mar;150(3):266-72. doi: 10.1001/jamadermatol.2013.8175.

PMID:
24429657
17.

Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study.

Arkachaisri T, Vilaiyuk S, Torok KS, Medsger TA Jr.

Rheumatology (Oxford). 2010 Feb;49(2):373-81. doi: 10.1093/rheumatology/kep361. Epub 2009 Dec 14.

18.

Reliability and validity of the myositis disease activity assessment tool.

Sultan SM, Allen E, Oddis CV, Kiely P, Cooper RG, Lundberg IE, Vencovsky J, Isenberg DA.

Arthritis Rheum. 2008 Nov;58(11):3593-9. doi: 10.1002/art.23963.

19.

The Localized Scleroderma Cutaneous Assessment Tool: responsiveness to change in a pediatric clinical population.

Kelsey CE, Torok KS.

J Am Acad Dermatol. 2013 Aug;69(2):214-20. doi: 10.1016/j.jaad.2013.02.007. Epub 2013 Apr 4.

20.

The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists.

Tiao J, Feng R, Bird S, Choi JK, Dunham J, George M, Gonzalez-Rivera TC, Kaufman JL, Khan N, Luo JJ, Micheletti R, Payne AS, Price R, Quinn C, Rubin AI, Sreih AG, Thomas P, Okawa J, Werth VP.

Br J Dermatol. 2017 Feb;176(2):423-430. doi: 10.1111/bjd.15140. Epub 2016 Dec 22.

PMID:
28004387

Supplemental Content

Support Center